A shift in glutamine nitrogen metabolism contributes to the malignant progression of cancer

Manabu Kodama; Kiyotaka Oshikawa; Hideyuki Shimizu; Susumu Yoshioka; Masatomo Takahashi; Yoshihiro Izumi; Takeshi Bamba; Chisa Tateishi; Takeshi Tomonaga; Masaki Matsumoto; Keiichi I. Nakayama

doi:10.1038/s41467-020-15136-9

A shift in glutamine nitrogen metabolism contributes to the malignant progression of cancer

Manabu Kodama, Kiyotaka Oshikawa, Hideyuki Shimizu, Susumu Yoshioka, Masatomo Takahashi, Yoshihiro Izumi, Takeshi Bamba, Chisa Tateishi, Takeshi Tomonaga, Masaki Matsumoto, Keiichi I. Nakayama

Research output: Contribution to journal › Article

Abstract

Glucose metabolism is remodeled in cancer, but the global pattern of cancer-specific metabolic changes remains unclear. Here we show, using the comprehensive measurement of metabolic enzymes by large-scale targeted proteomics, that the metabolism both carbon and nitrogen is altered during the malignant progression of cancer. The fate of glutamine nitrogen is shifted from the anaplerotic pathway into the TCA cycle to nucleotide biosynthesis, with this shift being controlled by glutaminase (GLS1) and phosphoribosyl pyrophosphate amidotransferase (PPAT). Interventions to reduce the PPAT/GLS1 ratio suppresses tumor growth of many types of cancer. A meta-analysis reveals that PPAT shows the strongest correlation with malignancy among all metabolic enzymes, in particular in neuroendocrine cancer including small cell lung cancer (SCLC). PPAT depletion suppresses the growth of SCLC lines. A shift in glutamine fate may thus be required for malignant progression of cancer, with modulation of nitrogen metabolism being a potential approach to SCLC treatment.

Original language	English
Article number	1320
Journal	Nature communications
Volume	11
Issue number	1
DOIs	https://doi.org/10.1038/s41467-020-15136-9
Publication status	Published - Dec 1 2020

All Science Journal Classification (ASJC) codes

Chemistry(all)
Biochemistry, Genetics and Molecular Biology(all)
Physics and Astronomy(all)

Access to Document

10.1038/s41467-020-15136-9

Fingerprint Dive into the research topics of 'A shift in glutamine nitrogen metabolism contributes to the malignant progression of cancer'. Together they form a unique fingerprint.

Cite this

Kodama, M., Oshikawa, K., Shimizu, H., Yoshioka, S., Takahashi, M., Izumi, Y., Bamba, T., Tateishi, C., Tomonaga, T., Matsumoto, M., & Nakayama, K. I. (2020). A shift in glutamine nitrogen metabolism contributes to the malignant progression of cancer. Nature communications, 11(1), [1320]. https://doi.org/10.1038/s41467-020-15136-9

A shift in glutamine nitrogen metabolism contributes to the malignant progression of cancer. / Kodama, Manabu; Oshikawa, Kiyotaka; Shimizu, Hideyuki; Yoshioka, Susumu; Takahashi, Masatomo; Izumi, Yoshihiro ; Bamba, Takeshi; Tateishi, Chisa; Tomonaga, Takeshi; Matsumoto, Masaki; Nakayama, Keiichi I.

In: Nature communications, Vol. 11, No. 1, 1320, 01.12.2020.

Research output: Contribution to journal › Article

@article{c9a9cbfa067e42b1b290d8c0d7d7552a,

title = "A shift in glutamine nitrogen metabolism contributes to the malignant progression of cancer",

abstract = "Glucose metabolism is remodeled in cancer, but the global pattern of cancer-specific metabolic changes remains unclear. Here we show, using the comprehensive measurement of metabolic enzymes by large-scale targeted proteomics, that the metabolism both carbon and nitrogen is altered during the malignant progression of cancer. The fate of glutamine nitrogen is shifted from the anaplerotic pathway into the TCA cycle to nucleotide biosynthesis, with this shift being controlled by glutaminase (GLS1) and phosphoribosyl pyrophosphate amidotransferase (PPAT). Interventions to reduce the PPAT/GLS1 ratio suppresses tumor growth of many types of cancer. A meta-analysis reveals that PPAT shows the strongest correlation with malignancy among all metabolic enzymes, in particular in neuroendocrine cancer including small cell lung cancer (SCLC). PPAT depletion suppresses the growth of SCLC lines. A shift in glutamine fate may thus be required for malignant progression of cancer, with modulation of nitrogen metabolism being a potential approach to SCLC treatment.",

author = "Manabu Kodama and Kiyotaka Oshikawa and Hideyuki Shimizu and Susumu Yoshioka and Masatomo Takahashi and Yoshihiro Izumi and Takeshi Bamba and Chisa Tateishi and Takeshi Tomonaga and Masaki Matsumoto and Nakayama, {Keiichi I.}",

year = "2020",

month = dec,

day = "1",

doi = "10.1038/s41467-020-15136-9",

language = "English",

volume = "11",

journal = "Nature Communications",

issn = "2041-1723",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - A shift in glutamine nitrogen metabolism contributes to the malignant progression of cancer

AU - Kodama, Manabu

AU - Oshikawa, Kiyotaka

AU - Shimizu, Hideyuki

AU - Yoshioka, Susumu

AU - Takahashi, Masatomo

AU - Izumi, Yoshihiro

AU - Bamba, Takeshi

AU - Tateishi, Chisa

AU - Tomonaga, Takeshi

AU - Matsumoto, Masaki

AU - Nakayama, Keiichi I.

PY - 2020/12/1

Y1 - 2020/12/1

N2 - Glucose metabolism is remodeled in cancer, but the global pattern of cancer-specific metabolic changes remains unclear. Here we show, using the comprehensive measurement of metabolic enzymes by large-scale targeted proteomics, that the metabolism both carbon and nitrogen is altered during the malignant progression of cancer. The fate of glutamine nitrogen is shifted from the anaplerotic pathway into the TCA cycle to nucleotide biosynthesis, with this shift being controlled by glutaminase (GLS1) and phosphoribosyl pyrophosphate amidotransferase (PPAT). Interventions to reduce the PPAT/GLS1 ratio suppresses tumor growth of many types of cancer. A meta-analysis reveals that PPAT shows the strongest correlation with malignancy among all metabolic enzymes, in particular in neuroendocrine cancer including small cell lung cancer (SCLC). PPAT depletion suppresses the growth of SCLC lines. A shift in glutamine fate may thus be required for malignant progression of cancer, with modulation of nitrogen metabolism being a potential approach to SCLC treatment.

AB - Glucose metabolism is remodeled in cancer, but the global pattern of cancer-specific metabolic changes remains unclear. Here we show, using the comprehensive measurement of metabolic enzymes by large-scale targeted proteomics, that the metabolism both carbon and nitrogen is altered during the malignant progression of cancer. The fate of glutamine nitrogen is shifted from the anaplerotic pathway into the TCA cycle to nucleotide biosynthesis, with this shift being controlled by glutaminase (GLS1) and phosphoribosyl pyrophosphate amidotransferase (PPAT). Interventions to reduce the PPAT/GLS1 ratio suppresses tumor growth of many types of cancer. A meta-analysis reveals that PPAT shows the strongest correlation with malignancy among all metabolic enzymes, in particular in neuroendocrine cancer including small cell lung cancer (SCLC). PPAT depletion suppresses the growth of SCLC lines. A shift in glutamine fate may thus be required for malignant progression of cancer, with modulation of nitrogen metabolism being a potential approach to SCLC treatment.

UR - http://www.scopus.com/inward/record.url?scp=85082054494&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85082054494&partnerID=8YFLogxK

U2 - 10.1038/s41467-020-15136-9

DO - 10.1038/s41467-020-15136-9

M3 - Article

C2 - 32184390

AN - SCOPUS:85082054494

VL - 11

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

IS - 1

M1 - 1320

ER -